Last updated: 2026-09-07 06:15:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Delcath Systems Inc. (DCTH) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $16.48, with a market capitalization of $575.31M and a P/E ratio of 1.07K. Over the past 52 weeks, its price has ranged from $8.12 to $17.42. This page covers its latest market performance, valuation, price trends and company information.
$575.31M | |
$16.32 | |
$801,248,000,000.00 | |
$2.25 | |
$16.48 | |
136.63K | |
-- | |
1,074.88 | |
$17.42 | |
$8.12 | |
-- | |
-- |
Delcath Systems Inc. (DCTH) last closed at $16.48 as of 2026-09-04 23:31:00, unchanged from the previous close of $16.48.
During the latest regular trading session, DCTH traded between $2.25 and $801,248,000,000.00, with a volume of 136.63K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Delcath Systems Inc. (DCTH) moved from $16.27 to $16.48, representing a gain of 1.27% ($0.21).
The stock traded between $16.25 and $16.48 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 364.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 89.8%
DCTH is currently trading at $16.48, placing it 89.8% of the way from its 52-week low of $8.12 to its 52-week high of $17.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 156 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Delcath Systems Inc. (DCTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.